<qa>  What is the dose of RoActemraActemra?This open-label, single arm study will evaluate the safety and efficacy of RoActemraActemra tocilizumab in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs DMARDs or anti-TNF. Patients will receive RoActemraActemra at a dose of 8 mgkg max 800 mg intravenously every 4 weeks for a total of 6 infusions. Non-biologic DMARD therapy may be continued throughout the study. Anticipated time on study treatment is 24 weeks. 